Annual Diaceutics Report Illuminates State of Diagnostic Ecosystem in the Pharmaceutical Industry

Across the 23 companies analyzed in this year's report, more than US$200 billion of annual therapy revenue is dependent on an efficient diagnostic testing ecosystem

DUNDALK, IRELAND and PARSIPPANY, NJ--(Marketwired - Dec 14, 2016) - Today, Diaceutics, a global group of experts from the laboratory, diagnostics and pharmaceutical industries, enabling pharmaceutical companies to leverage diagnostic testing, released its annual Pharma Readiness for Diagnostics Report. The report, which will be presented in a webinar today, is an assessment of 23 pharmaceutical and biotechnology companies with commercial therapies whose clinical and financial impact is highly dependent on the availability or efficiency of specific diagnostic tests. 

"Those of us who see the untapped diagnostic opportunities across the treatment pathway have a key task in front of us - namely to quantify, analyze and communicate with evidence to pharma asset and financial leaders how $1 invested smartly in the diagnostic ecosystem will return $40-$60 in new therapy revenue and, more importantly, get the right patients on the right therapies," said Peter Keeling, CEO of Diaceutics. "Currently, the diagnostic ecosystem underpinning the pharmaceutical business model is opaque, yet it is such an essential driver in delivering the financial as well as clinical potential of precision medicine."

Key findings from this year's report include:

  • 70 percent of late-stage and in-registration candidate therapies across the 23 companies profiled are dependent upon an efficient diagnostic strategy to support revenue growth.
  • Based on 1H 2016 data, it is expected that diagnostically enabled revenue from nearly 300 therapies across the 23 companies will grow 5-10 percent from 2015 levels.
  • Better leverage of diagnostics has the potential to unlock access to additional patients and drug revenue. For example, optimizing the potential of a still underdeveloped PD-L1 testing market could help to realize an additional US$740 million in lifecycle drug revenues per major indication.
  • Diagnostic strategies are increasingly being reflected in share price with 10 percent value premium for those companies most actively integrating diagnostics.
  • 2016 is set to be a record year for pharma/diagnostic-related partnerships with nearly 60 agreements already sealed in the first 9 months, an increase of 60 percent on the same period in 2015.
  • The oncology pipeline has largely converted to diagnostics-enabled prescribing but other indications including inflammatory diseases and diabetes pipelines, are also now highly diagnostic-enabled.
  • A number of forward predictions for 2017-2020, including the likely scrapping of FDA LDT regulations and resulting preference for laboratory versus diagnostic company partnerships to drive timely test adoption.

The Diaceutics report includes a comprehensive review and update of 23 pharmaceutical and biotechnology companies with at least one diagnostically-enabled therapy on the market or significant pipeline investment in biomarkers, and ranks them according to their potential to capitalize on opportunities in diagnostic test-driven markets. In this year's Diaceutics Pharma Readiness Index, the 23 companies fell into three categories:

  • First Movers: AstraZeneca, BMS, Merck and Pfizer now join Janssen, Novartis and Roche as first-movers in the market and are most likely to leverage diagnostics in the majority of their future marketed therapies.
  • Fast Followers: A group of companies including AbbVie, Bayer, Boehringer Ingelheim, Celgene, Eisai, EMD Serono, Lilly and Takeda fall into the Fast Followers segment - rated as integrating diagnostics into a selection, but not the majority, of their commercial therapy programs.
  • PM Planners: The remaining competitors are grouped as PM Planners, those actively planning the integration of testing into future launch programs, and include Amgen, Astellas Pharma, Bayer, Daiichi Sankyo, Gilead Sciences, GSK, Sanofi and Teva.

"We expect Teva, Astellas and Daiichi to join the Fast Followers in 2017-18 based on their increased diagnostics focus in pipeline planning and their partnering trajectory," added Keeling. "A strong, early diagnostic-driven pipeline may result in GSK and Sanofi climbing up the index, but only from 2020 onwards."

The analyses included a detailed quantitative and qualitative review of each company based on publicly available information, interviews with industry leaders, and an evaluation and company ranking derived from Diaceutics' proprietary analysis of the data available on the 23 companies. Company analysis included a review of corporate structure and leadership, R&D structure, phase III pipeline, management and marketing of existing therapies, business deals and strategic partnerships and communications.

Highlights from the report will be delivered by Diaceutics' Ewelina Golebiewska, PhD, Data Analyst and Steve Vitale, Managing Director, during an online webinar December 14, 2017 from 11:00am - 12:00pm EST. For more information please visit:

About Diaceutics Group
Diaceutics, a global group of experts from the laboratory, diagnostics and pharmaceutical industries, enables pharmaceutical companies to leverage diagnostic testing. Through a real-time flow of testing data from a worldwide laboratory network, Diaceutics helps its clients understand and leverage the diagnostic landscape so they can successfully integrate testing into treatment pathways. For more information, please visit or follow Diaceutics Group on Twitter, LinkedIn or YouTube.

Contact Information:

Media Contact
Colin Sanford
(415) 870-9188